Glooko, Inc., an integrated digital health firm that focuses on connecting healthcare providers, biopharma, medical device partners, and patients, has raised $100 million in Series F financing round.
The round, which was spearheaded by Georgian, with significant contributions from Canaan, Health Catalyst Capital, and other strategic partners will help support device integration, advancement in expert data insight, clinical research, advancement in chronic condition support, and continued growth.
As part of the company’s latest developments, its Board of Directors has appointed Mike Alvarez as Chief Executive Officer to steer the company’s growth and expansion. The new CEO will oversee the expansion of the company’s advanced digital healthcare platform as well as other works in life sciences.
Revolutionizing Connected Care
Glooko’s platform aims to help healthcare professionals working with patients to manage chronic conditions such as diabetes to navigate intricate challenges associated with clinical workflows and data burden by unifying the data from different devices into a single standardized platform.
This simplifies the decision-making process for healthcare professionals, allowing them to transform vast amounts of data into valuable insights for timely interventions and creating new therapy pathways for improved patient outcomes.
The platform synchronizes seamlessly with diabetes devices, activity trackers, and fitness wearables, generating health reports and analytics, empowering diabetes patients to manage their conditions and stay connected to their care professionals for improved care outcomes.
According to Glooko, its platform has so far served over 4 million patients, integrated over 200 medical devices, and connected over 10,000 health facilities across 30 countries, offering services in more than 20 languages.